Omalizumab (Xolair)
A previous CADTH Common Drug Review (CDR) of the use of omalizumab for allergic asthma in 2006 led to the recommendation by the Canadian Expert Drug Advisory Committee that omalizumab not be reimbursed due to: insufficient evidence that omalizumab improves exacerbations that lead to hospitalizations...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
CADTH
September 2017, 2017
|
| Series: | Common drug review clinical review report
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Table of Contents:
- Includes bibliographical references